APA (7th ed.) Citation

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., . . . Roden, M. (2020). Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes care, 43(2), 298. https://doi.org/10.2337/dc19-0641

Chicago Style (17th ed.) Citation

Kahl, Sabine, et al. "Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial." Diabetes Care 43, no. 2 (2020): 298. https://doi.org/10.2337/dc19-0641.

MLA (9th ed.) Citation

Kahl, Sabine, et al. "Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial." Diabetes Care, vol. 43, no. 2, 2020, p. 298, https://doi.org/10.2337/dc19-0641.